Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide.  Some background Treatment for metastatic...

Read More

Which prostate cancer patients are at risk of skeletal related events?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated whether the likelihood of developing skeletal related events (SREs) could be determined depending on the site of metastasis at diagnosis and other factors in older patients with prostate cancer. The study concluded that the likelihood of developing an SRE was similar among different sites of metastasis, except...

Read More

The use of circulating tumor cells in predicting survival in chemotherapy patients

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to investigate if circulating tumor cells (CTC) levels in the blood could be used to determine the outcome for metastatic castration resistant prostate cancer patients. This study concluded that CTC levels could be used to predict survival in these patients.  Some background Treatment for metastatic...

Read More

The timing of first biopsy and its effect on prostate cancer reclassification

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance.  The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...

Read More

Prostate cancer treatments for elderly men

Posted by on Mar 6, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to identify the recommended treatments for prostate cancer in men over the age of 70 years. The authors concluded that treatments for local and advanced prostate cancer in elderly men should be individualized, with focus on the health of the patient, to determine the appropriate treatment course. Some background...

Read More

The effect of anxiety and uncertainty on men under prostate cancer active surveillance

Posted by on Mar 4, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance.  The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...

Read More

Can sentinel lymph node dissection be used to identify patients who could benefit from further therapy?

Posted by on Mar 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of the study was to examine if sentinel lymph node dissection (SLND) could be used to select patients with prostate cancer who would benefit from further pelvic radiation therapy and long-term androgen deprivation therapy (ADT). It was concluded that SLND could be used as a tool to determine whether patients should have more...

Read More